Ulocuplumab
Modify Date: 2024-09-16 13:55:32
Ulocuplumab structure
|
Common Name | Ulocuplumab | ||
|---|---|---|---|---|
| CAS Number | 1375830-34-4 | Molecular Weight | 146.2 (kDa) | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of UlocuplumabUlocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models[1][2]. |
| Name | Ulocuplumab |
|---|
| Description | Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models[1][2]. |
|---|---|
| Related Catalog | |
| Target |
CXCR4 |
| In Vitro | Ulocplumab (0-100 μM; 48 h) 缺乏抗体依赖的细胞细胞毒性 (ADCC) 或补体 (CDC) 活性，但也在 Ramos 细胞和 CLL 或癌细胞系中诱导 CXCR4 结合介导的凋亡，也在 CLL 患者的原发性白血病细胞中显示促凋亡[1]。 Ulocplumab (0.2 μM, 2 μM; 15 s) 抑制 F-actin 聚合，降低对 CXCL12 的峰响应，(20 nM-2 μM; 1 h) 还抑制细胞迁移[1]。 Ulocplumab (200 nM; 6 h) 具有独立于 caspase 的程序性细胞死亡 (PCD) 诱导作用[1]。 Ulocplumab (10 μg/mL; 4 h) 在CLL细胞中通过产生活性氧 (ROS) 诱导细胞死亡[1]。 Ulocplumab 抑制 CXCL12 诱导的钙通量，在 Ramos 中 EC50 为 10 nM [2]。 Apoptosis Analysis[1] Cell Line: Ramos cells and primary leukemia cells (from CLL patients) Concentration: 0-100 μM Incubation Time: 48 hours Result: Induced apoptosis in Ramos cells with an IC50 value of 1.9 nM and showed pro-apoptotic with an IC50 value of 12.43 nM in primary leukemia cells from CLL patients. |
| In Vivo | Ulocplumab (3-30 mg/kg; 腹腔注射; 3-4 天 5 次剂量; 共 65 天) 抑制小鼠多发性骨髓瘤异种移植瘤模型的肿瘤生长，包括带有 Ramos B 细胞、HL-60 细胞、MOLP-8 细胞、Nomo-1 细胞和 JJN-3R 细胞的肿瘤模型[1]。 Animal Model: Severe combined immunodeficient (SCID) mice of AML model (MOLP-8 cells)[1] Dosage: 3-30 mg/kg Administration: Intraperitoneal injection; every 3-4 days for 5 doses; last for 65 days Result: Significantly delayed mean tumor growth by 66% and 56% when compared with isotype control on day 25. |
| References |
| Molecular Weight | 146.2 (kDa) |
|---|